Protocol Ledger

NCT03597022 · Phase II · TERMINATED

Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors

Interventional Phase II clinical trial protocol NCT03597022 sponsored by Bayer in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-07-24 Enrollment: 24 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03597022
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)24 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03597022
Protocol FieldVerified Registry Value
NCT IdentifierNCT03597022
Consolidated Lead SponsorBayer
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment24 participants (ACTUAL)
Registered Start Date2018-07-24
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03597022
Hospital Research SiteLocationSite Profile
Fiona Stanley HospitalMurdoch, AustraliaOpen Hospital Dossier ->
Fondazione IRCCS CA' Granda Ospedale Maggiore PoliclinicoMilan, ItalyOpen Hospital Dossier ->
Hiroshima University HospitalHiroshima, JapanOpen Hospital Dossier ->
Changhua Christian HospitalChanghua, TaiwanOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI